» Articles » PMID: 32244301

Treatment of Delirium in Older Persons: What We Should Not Do!

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 Apr 5
PMID 32244301
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The presentation of common acute diseases in older age is often referred to as "atypical". Frequently, the symptoms are neither single nor tissue related. In most cases, the onset of symptoms and diseases is the expression of a diminished reserve with a failure of the body system and imbalance of brain function. Delirium is one of the main devastating and prevalent atypical symptoms and could be considered as a geriatric syndrome. It encompasses an array of neuropsychiatric symptoms and represents a disarrangement of the cerebral function in response to one or more stressors. The most recent definition, reported in the DSM-V, depicts delirium as a clear disturbance in attention and awareness. The deficit is to be developed in a relatively short time period (usually hours or days). The attention disorder must be associated with another cognitive impairment in memory, orientation, language, visual-spatial or perception abilities. For the treatment, it is imperative to remove the potential causes of delirium before prescribing drugs. Even a non-pharmacological approach to reducing the precipitating causes should be identified and planned. When we are forced to approach the pharmacological treatment of hyperactive delirium in older persons, we should select highly cost-effective drugs. High attention should be devoted to the correct balance between improvement of psychiatric symptoms and occurrence of side effects. Clinicians should be guided in the correct choice of drugs following cluster symptoms presentation, excluding drugs that could potentially produce complications rather than advantages. In this brief point-of-view, we propose a novel pharmacological flow-chart of treatment in relation to the basic clusters of diseases of an older patient acutely admitted to the hospital and, in particular, we emphasize "What We Should Not Do!", with the intention of avoiding possible side effects of drugs used.

Citing Articles

Drug prescriptions in elderly hospitalized patients with cognitive impairment in the Italian Dementia Friendly Hospital project.

Govoni S, Rosi A, Preda S, Lanni C, Cappa S, Allegri N Front Pharmacol. 2024; 15:1474986.

PMID: 39600363 PMC: 11588458. DOI: 10.3389/fphar.2024.1474986.


Improving delirium assessments in acute senior health: A quality improvement project for care of the older person.

Taylor C, Peakman G, Mackinnon L, Mohamadzade N, Han W, Mackie L BMC Geriatr. 2024; 24(1):781.

PMID: 39322946 PMC: 11423504. DOI: 10.1186/s12877-024-05273-x.


Delirium Knowledge, Risk Factors, and Attitude Among the General Public in Saudi Arabia: A Cross-Sectional Study.

Alshurtan K, Ali Alshammari F, Alshammari A, Alreheili S, Aljassar S, Alessa J Cureus. 2024; 16(4):e59263.

PMID: 38813288 PMC: 11134522. DOI: 10.7759/cureus.59263.


Relationship Between Delirium Development and Its Causative Factors in the Intensive Care Unit After Cardiac Surgery.

Hori Y, Mihashi M Yonago Acta Med. 2023; 66(2):214-222.

PMID: 37229376 PMC: 10203640. DOI: 10.33160/yam.2023.05.003.


Knowledge, attitude, and practice toward delirium and subtype assessment among Chinese clinical nurses and determinant factors: A multicentre cross-section study.

Zhou W, Zheng Q, Huang M, Zhang C, Zhang H, Yang L Front Psychiatry. 2023; 13:1017283.

PMID: 36819944 PMC: 9929153. DOI: 10.3389/fpsyt.2022.1017283.


References
1.
Inouye S, Bogardus Jr S, Baker D, Leo-Summers L, Cooney Jr L . The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program. J Am Geriatr Soc. 2000; 48(12):1697-706. DOI: 10.1111/j.1532-5415.2000.tb03885.x. View

2.
Mocci G, Jimenez-Sanchez L, Adell A, Cortes R, Artigas F . Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action. Neuropharmacology. 2013; 79:49-58. DOI: 10.1016/j.neuropharm.2013.10.021. View

3.
Kukkar A, Bali A, Singh N, Jaggi A . Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013; 36(3):237-51. DOI: 10.1007/s12272-013-0057-y. View

4.
Morandi A, Pozzi C, Milisen K, Hobbelen H, Bottomley J, Lanzoni A . An interdisciplinary statement of scientific societies for the advancement of delirium care across Europe (EDA, EANS, EUGMS, COTEC, IPTOP/WCPT). BMC Geriatr. 2019; 19(1):253. PMC: 6739939. DOI: 10.1186/s12877-019-1264-2. View

5.
Sultzer D, Gray K, Gunay I, Berisford M, MAHLER M . A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry. 1997; 5(1):60-9. View